Lexaria Bioscience Corp.
LEXX
$1.35
-$0.34-20.12%
NASDAQ
| 02/28/2025 | 11/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -5.38% | 118.93% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -5.38% | 118.93% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -3.97% | 115.71% | |||
| SG&A Expenses | 34.88% | -27.20% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.75% | 28.95% | |||
| Operating Income | -2.24% | -25.43% | |||
| Income Before Tax | -0.38% | -23.78% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -0.38% | -23.78% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 31.03% | 61.11% | |||
| Net Income | -0.35% | -23.75% | |||
| EBIT | -2.24% | -25.43% | |||
| EBITDA | -3.43% | -24.83% | |||
| EPS Basic | 4.50% | -16.61% | |||
| Normalized Basic EPS | 2.68% | -18.61% | |||
| EPS Diluted | 4.50% | -16.61% | |||
| Normalized Diluted EPS | 2.68% | -18.61% | |||
| Average Basic Shares Outstanding | 5.06% | 6.09% | |||
| Average Diluted Shares Outstanding | 5.06% | 6.09% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||